Original Research
Published on 11 Sep 2023
Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib
in Hematologic Malignancies
- 1,701 views
- 1 citation
Original Research
Published on 11 Sep 2023
in Hematologic Malignancies
Mini Review
Published on 11 Sep 2023
in Hematologic Malignancies
Original Research
Published on 08 Sep 2023
in Hematologic Malignancies
Case Report
Published on 08 Sep 2023
in Hematologic Malignancies
Original Research
Published on 08 Sep 2023
in Hematologic Malignancies
Case Report
Published on 07 Sep 2023
in Hematologic Malignancies
Mini Review
Published on 06 Sep 2023
in Hematologic Malignancies
Original Research
Published on 31 Aug 2023
in Hematologic Malignancies
Review
Published on 30 Aug 2023
in Hematologic Malignancies
Editorial
Published on 30 Aug 2023
in Hematologic Malignancies
Case Report
Published on 28 Aug 2023
in Hematologic Malignancies
Original Research
Published on 28 Aug 2023
in Hematologic Malignancies
Review
Published on 28 Aug 2023
in Hematologic Malignancies
Original Research
Published on 22 Aug 2023
in Hematologic Malignancies
Correction
Published on 21 Aug 2023
in Hematologic Malignancies
Original Research
Published on 21 Aug 2023
in Hematologic Malignancies